Uncategorized

BioMarin Surpasses Analysts’ Q3 Sales Estimates Despite Voxzogo’s Slight Miss

The biotech beat Wall Street’s third-quarter revenue forecast by 6%, driven by increased uptake of its achondroplasia drug Voxzogo. However, William Blair downgraded BioMarin’s shares to market perform due to a “lack of near-term catalysts” and uncertainty around Voxzogo’s potential revenue growth.

BioMarin Surpasses Analysts’ Q3 Sales Estimates Despite Voxzogo’s Slight Miss Read More »

Scroll to Top